In our model, the combination of 100 nm dasatinib with 25 μm U0126 showed a significant reduction in survival of IM‐resistant cells, as well as significant reduction in the ability of CML CD34+ cells to form colonies in methylcellulose assays. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.